Baxter, Otsuka Holdings Co., Ltd. and Fresenius Kabi AG are Dominating the Morocco Parenteral Nutrition Market in 2021

Morocco Parenteral Nutrition Market is expected to grow with the CAGR of 3.3% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below.

Access Full Report @  https://www.databridgemarketresearch.com/reports/morocco-parenteral-nutrition-market

Morocco's parenteral nutrition market is a highly consolidated market, which includes a specific number of key players. The market has witnessed increased strategic developments owing to favorable market scenario.

The major players dealing in Morocco parenteral nutrition market are introducing a strong range of products provider along with launching new products and adopting strategic initiative such as acquisition, agreement, business expansion, award and recognition into the market. This helped companies to maximize the sales with an enhanced product portfolio.

For instance:

  • In September 2020, Baxter announced the U.S. F.D.An approval of Clinimix and Clinimix E for Patients Requiring Parenteral Nutrition. The novel clinimix formulations contain up to 80 g/L of amino acids, the highest protein in any multi-chamber bag available in the U.S. The approval received would provide timely treatment of individuals and would be submitted for post market approval.

Baxter is the dominating player in Morocco parenteral nutrition market. The other key players existing in the market are Otsuka Holdings Co., Ltd., Pfizer Inc., Fresenius Kabi AG, Hikma pharmaceutical PLC, and VIFOR PHARMA MANAGEMENT LTD., among others.

Morocco Parenteral Nutrition MarketBaxter

Baxter, headquarter is in Illinois, the U.S. The company is focused on becoming one of the best companies in the field of innovation, development of nutritional products, drugs and vaccines that will be beneficial to both the consumers and the company. The company has several product & service categories including acute and chronic dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anaesthetics, generic injectable pharmaceuticals and surgical in which parenteral nutrition therapies is the market focused category.

For instance,

  • In September 2020, Baxter announced the U.S. F.D.A approval of Clinimix and Clinimix E for Patients Requiring Parenteral Nutrition. The novel clinimix formulations contain up to 80 g/L of amino acids, the highest protein in any multi-chamber bag available in the U.S. The approval received would provide timely treatment of individuals and would be submitted for post market approval.

The company has wide presence across Americas, Asia-Pacific, Europe, Middle East, and Africa. The company also has various subsidiaries, including Baxter S.p.A.(Italy), Gambro (Sweden), Baxter S.A.S. (France), Baxter India Private Limited (India), Baxter Medical AB (Sweden), among others.

Otsuka Holdings Co., Ltd.

Otsuka Holdings Co., Ltd., founded in the year 1964, headquarter in New Jersey, U.S. Their main focus of the company is to innovate challenging healthcare solutions. The company any operates its business via several business segments, including innovative medicines and Otsuka pharmaceuticals in which innovative medicines is the market focused segment. The company has product categories which are infusion therapies, pain management, parenteral nutrition, plasma volume expanders, and eternal nutrition, in which parenteral nutrition is the market-focused category.

For instance,

In September 2020, Otsuka Holdings Co., Ltd. received the post marketing approval for ENEFLUID Injection, the amino acid, glucose, electrolyte, fat, and water-soluble vitamin injection. The product is the first peripheral parenteral nutrition solution in Japan that combines fat and water-soluble vitamins in addition to glucose, electrolytes, and amino acids in a dual-chamber bag. The post marketing approval received would result in robust supply of the carbohydrate parenteral nutrition.

The company has presence across North America, Asia-Pacific, Europe, Middle East, and Africa.

Fresenius Kabi AG

Fresenius Kabi AG founded in the year 1999, headquartered in Bad Homburg, Germany. The main focus of the company is to create value for the stockholders, customers and employees while strengthening its seaming power. The company operates its business via several business segments including Enteral Nutrition, I.V. Drugs, Infusion Therapy, Oncology Drugs, Oral Amino, Keto Acids, Parenteral Nutrition, in which Parenteral nutrition is the market focused category.

The company has presence across North America, Asia-Pacific, Europe, Middle East and Africa.